Financial reports
10-K
2023 FY
Annual report
16 Apr 24
NT 10-K
Notice of late annual filing
2 Apr 24
10-Q
2023 Q3
Quarterly report
14 Nov 23
ARS
2022 FY
Annual report to shareholders
3 Nov 23
10-Q
2023 Q2
Quarterly report
14 Aug 23
10-Q
2023 Q1
Quarterly report
15 May 23
10-K
2022 FY
Annual report
31 Mar 23
10-Q
2022 Q3
Quarterly report
14 Nov 22
10-Q
2022 Q2
Quarterly report
15 Aug 22
10-Q
2022 Q1
Quarterly report
16 May 22
Current reports
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
18 Mar 24
8-K
Entry into a Material Definitive Agreement
12 Mar 24
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
11 Mar 24
8-K
Departure of Directors or Certain Officers
28 Feb 24
8-K
Departure of Directors or Certain Officers
21 Feb 24
8-K
BioSig’s PURE EP™ Platform with New Near Field Tracking Algorithm Surpasses 100 Patient Cases
6 Feb 24
8-K/A
Cost Associated with Exit or Disposal Activities
2 Feb 24
8-K
Cost Associated with Exit or Disposal Activities
1 Feb 24
8-K
BioSig Announces Reverse Stock Split
31 Jan 24
8-K
BioSig Announces Cost Reductions to Improve its Financial Standing and Shifts its Core Strategy
30 Jan 24
Registration and prospectus
D
$1.48 mm in equity / options / securities to be acquired, sold $1.48 mm, 7 investors
16 Jan 24
S-3/A
Shelf registration (amended)
5 Jan 24
S-3
Shelf registration
28 Dec 23
424B5
Prospectus supplement for primary offering
13 Nov 23
D
$860.93 k in equity / options / securities to be acquired, sold $860.93 k, 20 investors
25 Oct 23
D
$1.17 mm in equity / options / securities to be acquired, sold $1.17 mm, 10 investors
6 Oct 23
D
$794.03 k in equity / options / securities to be acquired, sold $794.03 k, 4 investors
27 Sep 23
424B5
Prospectus supplement for primary offering
15 Sep 23
424B5
Prospectus supplement for primary offering
18 Aug 23
D
$2.20 mm in equity / options / securities to be acquired, sold $2.20 mm, 1 investor
1 Aug 23
Proxies
DEF 14A
Definitive proxy
1 Dec 23
PRE 14A
Preliminary proxy
21 Nov 23
DEFA14A
Additional proxy soliciting materials
3 Nov 23
DEF 14A
Definitive proxy
3 Nov 23
PRE 14A
Preliminary proxy
24 Oct 23
DEF 14A
Definitive proxy
29 Dec 22
DEFA14A
Additional proxy soliciting materials
7 Nov 22
DEF 14A
Definitive proxy
7 Nov 22
PRE 14A
Preliminary proxy
28 Oct 22
DEFA14A
Additional proxy soliciting materials
30 Apr 21
Other
EFFECT
Notice of effectiveness
13 Jan 21
CORRESP
Correspondence with SEC
8 Jan 21
UPLOAD
Letter from SEC
8 Jan 21
EFFECT
Notice of effectiveness
25 Jun 19
CORRESP
Correspondence with SEC
20 Jun 19
UPLOAD
Letter from SEC
11 Jun 19
EFFECT
Notice of effectiveness
7 May 19
EFFECT
Notice of effectiveness
5 Apr 19
EFFECT
Notice of effectiveness
5 Apr 19
EFFECT
Notice of effectiveness
1 Apr 19
Ownership
144
Notice of proposed sale of securities
11 Mar 24
4
Frederick Hrkac
4 Mar 24
SC 13G
ARMISTICE CAPITAL, LLC
14 Feb 24
4
Frederick Hrkac
4 Jan 24
4/A
John Sieckhaus
5 Dec 23
4/A
Gray Fleming
5 Dec 23
4
John Sieckhaus
4 Dec 23
4
Gray Fleming
4 Dec 23
4
KENNETH L LONDONER
4 Dec 23
4
IV David Weild
18 Aug 23